DelveInsight’s, “Diffuse Large B-cell Lymphoma (DLBCL) – Pipeline Insight, 2020,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Diffuse Large B-cell Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
• Global coverage
Diffuse Large B-cell Lymphoma Understanding
Diffuse Large B-cell Lymphoma (DLBCL): Overview
Lymphoma is a type of blood cancer that develops when white blood cells called lymphocytes grow out of control. Lymphocytes are part of your immune system. They travel around your body in your lymphatic system, helping you fight infections. There are two types of lymphocyte: T lymphocytes (T cells) and B lymphocytes (B cells). There are lots of different types of lymphoma. Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL). It is a fast-growing (high-grade) lymphoma. Diffuse Large B-cell Lymphoma is an aggressive (fast-growing) NHL that affects B-lymphocytes. Lymphocytes are one type of white blood cell. B-cells are lymphocytes that make antibodies to fight infections and are an important part of the lymphatic system.
Most people with Diffuse Large B-cell Lymphoma first notice painless lumps, often in their neck, armpit or groin. These are swollen (enlarged) lymph nodes. They usually grow quite quickly, over just a few weeks. Sometimes, Diffuse Large B-cell Lymphoma can develop in lymph nodes deep inside body where they can’t be felt from the outside.
The exact symptoms depend on where in body the Diffuse Large B-cell Lymphoma is. These are called local symptoms. They can be very variable depending on what organs or tissues are affected. For example:
Diffuse Large B-cell Lymphoma in stomach or bowel can cause tummy (abdominal) discomfort or pain, diarrhoea or bleeding. Diffuse Large B-cell Lymphoma in chest can cause a cough or breathlessness.
The main way to diagnose Diffuse Large B-cell Lymphoma is to remove a swollen lymph node, or a sample of cells from it, and look at it under a microscope. This involves a small operation called a biopsy, which is usually done under a local anaesthetic. The sample is also tested for particular proteins that are found on the surface of lymphoma cells. This can help medical team decide on the most appropriate treatment for you. There are other tests to find out which areas of body are affected by lymphoma. This is called staging. Staging usually involves having a PET scan and a CT scan. Some people, particularly children, may have an MRI scan.
The treatments commonly used on Diffuse Large B-cell Lymphoma are chemotherapy drugs, radiation treatments, or immunotherapy. Doctors may also prescribe a combination of the three treatments. The most common chemotherapy treatment is referred to as R-CHOP. R-CHOP stands for a combination of the chemotherapy and immunotherapy medications rituximab, cyclophosphamide, doxorubicin, and vincristine, along with prednisone. R-CHOP is given through an IV for four of the medications, and prednisone is taken by mouth. R-CHOP is usually administered every three weeks.
Diffuse Large B-cell Lymphoma Emerging Drugs Chapters
This segment of the Diffuse Large B-cell Lymphoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Diffuse Large B-cell Lymphoma Emerging Drugs
• YY-20394: Shanghai YingLi Pharmaceutical Co. Ltd.
YY-20394 is an orally available selective inhibitor of the delta form of phosphatidylinositol 3-kinase (PI3-kinase subunit delta; PI3K-delta; PI3Kdelta), with potential antineoplastic activity. Upon oral administration, PI3K-delta inhibitor YY-20394 selectively binds to and inhibits PI3K-delta and prevents the activation of the PI3K/AKT signaling pathway. This decreases proliferation of and induces cell death in PI3K-delta over-expressing tumor cells. PI3K-delta also plays a key role in the B-cell receptor (BCR) signaling pathway and the proliferation of certain hematologic cancer cells. The targeted inhibition of PI3K-delta is designed to preserve PI3K signaling in normal, non-neoplastic cells, thereby minimizing serious side effects.
• Mosunetuzumab- Hoffmann-La Roche
Mosunetuzumab is a bispecific, humanized monoclonal antibody with potential antineoplastic activity. Anti-CD20/CD3 bispecific monoclonal antibody BTCT4465A contains two antigen-recognition sites: one for human CD3, a T-cell surface antigen, and one for human CD20, a tumor-associated antigen (TAA) that is exclusively expressed on B cells during most stages of B-cell development and is often overexpressed in B-cell malignancies. Upon administration, BTCT4465A binds to both T cells and CD20-expressing tumor B cells; this cross-links T cells to tumor cells, and may result in a potent cytotoxic T-lymphocyte (CTL) response against CD20-expressing tumor B cells.
Further product details are provided in the report……..
Diffuse Large B-cell Lymphoma: Therapeutic Assessment
This segment of the report provides insights about the different Diffuse Large B-cell Lymphoma drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Diffuse Large B-cell Lymphoma
There are approx. 50+ key companies which are developing the therapies for Diffuse Large B-cell Lymphoma. The companies which have their Diffuse Large B-cell Lymphoma drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, MorphoSys, Kite, A Gilead Company, Karyopharm Therapeutics Inc., Chia Tai Tianqing Pharmaceutical Group Co., Ltd. etc.
DelveInsight’s report covers around 50+ products under different phases of clinical development like
• Mid-stage products (Phase II and Phase I/II)
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Diffuse Large B-cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Molecule Type
Products have been categorized under various Molecule types such as
• Small molecules
• Gene therapies
• CAR-T Therapies
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Diffuse Large B-cell Lymphoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Diffuse Large B-cell Lymphoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Diffuse Large B-cell Lymphoma drugs.
• The companies and academics are working to assess challenges and seek opportunities that could influence Diffuse Large B-cell Lymphoma R&D. The therapies under development are focused on novel approaches to treat/improve Diffuse Large B-cell Lymphoma.
• August 2020: Selpercatinib had durable efficacy, including intracranial activity, with mainly low-grade toxic effects in patients with RET fusion–positive Diffuse Large B-cell Lymphoma who had previously received platinum-based chemotherapy and those who were previously untreated.
Diffuse Large B-cell Lymphoma Report Insights
• Diffuse Large B-cell Lymphoma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs
Diffuse Large B-cell Lymphoma Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Diffuse Large B-cell Lymphoma drugs?
• How many Diffuse Large B-cell Lymphoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Diffuse Large B-cell Lymphoma?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Diffuse Large B-cell Lymphoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Diffuse Large B-cell Lymphoma and their status?
• What are the key designations that have been granted to the emerging drugs?
• A Gilead Company
• Karyopharm Therapeutics Inc.
• Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
• Incyte Corporation
• Autolus Limited
• Hoffmann-La Roche
• ADC Therapeutics S.A
• Xynomic Pharmaceuticals, Inc.
• Antengene Corporation
• Acerta Pharma BV
• Denovo Biopharma LLC
• L19-IL2 - Ph I
• AMG 562
Please Note: It will take 1 - 4 business days to complete the report upon order confirmation.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook